Literature DB >> 3391979

Clozapine-induced agranulocytosis: non-cross-reactivity with other psychotropic drugs.

J A Lieberman1, C A Johns, J M Kane, K Rai, A V Pisciotta, B L Saltz, A Howard.   

Abstract

Clozapine, an atypical neuroleptic with unique clinical and preclinical properties, represents a potentially valuable addition to the psychopharmacopeia. Its development and use have been limited by its higher frequency, compared with other pharmacologic treatments, of the potentially fatal side effect of agranulocytosis. This article describes the natural history of five cases of agranulocytosis that occurred in the course of clozapine treatment. The cases were generally uniform as to onset, recovery, and hematologic features. No patient had hematologic reactions to treatment with psychotropic agents before or after clozapine treatment. These findings, along with other work in progress, suggest that clozapine's granulocytoxic effects are produced by a highly specific immune-mediated mechanism.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3391979

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  19 in total

Review 1.  Clinical profile of clozapine: adverse reactions and agranulocytosis.

Authors:  J A Lieberman; A Z Safferman
Journal:  Psychiatr Q       Date:  1992

Review 2.  Psychiatry.

Authors:  K Granville-Grossman
Journal:  Postgrad Med J       Date:  1990-09       Impact factor: 2.401

3.  Olanzapine, a novel atypical antipsychotic, reverses d-amphetamine-induced inhibition of midbrain dopamine cells.

Authors:  M E Stockton; K Rasmussen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

4.  Clozapine--a new and different neuroleptic.

Authors:  E Haller; R L Binder
Journal:  West J Med       Date:  1990-07

5.  Agranulocytosis and significant leucopenia with neuroleptic drugs: results from the AMUP program.

Authors:  R Grohmann; L G Schmidt; C Spiess-Kiefer; E Rüther
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

6.  Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drug.

Authors:  B M Migler; E J Warawa; J B Malick
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Does eosinophilia predict clozapine induced neutropenia?

Authors:  M Hummer; B Sperner-Unterweger; G Kemmler; M Falk; M Kurz; H Oberbauer; W W Fleischhacker
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

8.  Treatment of severe borderline personality disorder with clozapine.

Authors:  Adarsh Kumar Vohra
Journal:  Indian J Psychiatry       Date:  2010-07       Impact factor: 1.759

Review 9.  Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia.

Authors:  A Fitton; R C Heel
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

Review 10.  Monitoring the safe use of clozapine: a consensus view from Victoria, Australia.

Authors:  Michael Berk; Joanna Fitzsimons; Timothy Lambert; Christos Pantelis; Jayashri Kulkarni; David Castle; Elizabeth W Ryan; Sean Jespersen; Pat McGorry; Gregor Berger; Bill Kuluris; Tom Callaly; Seetal Dodd
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.